A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes and obesity medications.

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...

But at the same time, industry leaders are bracing for the news that they think is inevitable given Trump’s declaration in ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.